基于mRNA疫苗生产技术特点,对照新近发布的《WHO预防传染病mRNA疫苗质量、安全及有效性评价法规考虑》,梳理评估现阶段预防传染病mRNA疫苗起始材料、原辅料和原液质量控制具体考虑要点,为我国预防传染病mRNA疫苗的研究和质控提供参考。
Based on the technical characteristics of mRNA vaccines production, the specific points for consideration of quality control of starting and raw materials, excipients and stock solution of mRNA vaccines for the prevention of infectious diseases at the present stage are sorted out and evaluated, comparison of newly released ‘WHO Regulatory Considerations for the Evaluation of the Quality, Safety and Efficacy of Messenger RNA Vaccines for the Prevention of Infectious Diseases’. These will provide references for the research and quality control of mRNA vaccines for the prevention of infectious diseasesin China.
[1] WHO.Weekly Epidemiological Update on COVID-19. Edition 89[EB/OL].(2022-04-27) [2022-04-29].https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-27-april-2022
[2] 刘芬,李雪,李香玉.我国新冠疫苗研制生产的监管特点分析[J].中国药事,2022,36(1):25
LIU F, LI X, LI XY. Analysis of regulatory characteristics of COVID-19 vaccine development and production in China[J].Chin Pharm Aff,2022,36(1):25
[3] ZHANG T, WU Q, ZHANG Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak[J].Curr Biol, 2020, 30(7):1346
[4] LI Z, LIU X, LIU M, et al. The effect of the COVID-19 vaccine on daily cases and deaths based on global vaccine data[J].Vaccines, 2021, 9(11):1328
[5] BOS R, RUTTEN L, VAN DER LUBBE JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses[J].NPJ Vaccines, 2020, 5(1):1
[6] OMER SB, YILDIRIM I, FORMAN HP. Herd immunity and implications for SARS-CoV-2 control[J].JAMA, 2020, 324(20):2095
[7] FDA. COVID-19 Vaccines Authorized for Emergency Use or FDA-Approved[EB/OL].(2021-12-01)[2021-12-07].https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
[8] JIA L, MAO Y, JI Q, et al. Decoding mRNA translatability and stability from the 5′ UTR[J].Nat Struct Mol Biol, 2020, 27(9):814
[9] 孙程洁,成殷,王冲.mRNA疫苗的研究进展及监管概述[J].中国药事,2022,36(1):3
SUN CJ, CHENG Y, WANG C.Research progress and regulatory overview of mRNA vaccine[J].Chin Pharm Aff,2022,36(1):3
[10] LIU T, LIANG Y, HUANG L. Development and delivery systems of mRNA vaccines[J].Front Bioeng Biotechnol, 2021, 9: 718753
[11] KARPENKO LI, RUDOMETOY AP, SHARABRIN SV, et al. Delivery of mrna vaccine against sars-cov-2 using a polyglucin: spermidine conjugate[J].Vaccines, 2021, 9(2):76
[12] WHOE Valuation of the Quality, Safety and Efficacy of Messenger RNA Vaccines for the Prevention of Infectious Diseases: Regulatory Considerations; TRS 1039, Annex 3[EB/OL].(2022-04-12) [2022-09-06].https://www.who.int/publications/i/item/9789240046870
[13] Good Manufacturing Practices: Supplementary Guidelines for the Manufacture of Pharmaceutical Excipients; TRS 885, Annex 5[EB/OL].(1999-06-01) [2022-09-20].https://www.who.int/publications/i/item/WHO_TRS_885
[14] Impurities: Guideline for Residual Solvents-Q3C(R6). ICH Harmonised Guideline.Final Version. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use[EB/OL].(2016-10-20) [2022-09-20].https://database.ich.org/sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf
[15] Guideline for Elemental Impurities-Q3D(R1). ICH Harmonised Guideline. Final Version: 22 March 2019. International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use[EB/OL].(2019-3-22) [2022-09-20].https://database.ich.org/sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf
[16] EMA. ICH Guideline S2 (R1) on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. Step 5[EB/OL].[2022-09-06].https://www.ema.europa.eu/en/documents/scientificguideline/ich-guideline-s2-r1-genotoxicity-testing-datainterpretation-pharmaceuticals-intended-human-usestep_en.pdf.
[17] MUI BL, TAM YK, JAYARAMAN M, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles[J].Mol Ther Nucleic Acids, 2013, 2(12):e139
[18] LEI D, SCHMIDT H, KNEZEVIC I, et al. Removal of the innocuity test from The International Pharmacopoeia and WHO recommendations for vaccines and biological products[J].Biologicals, 2020, 66:17
[19] Guidelines on Stability Evaluation of Vaccines//WHO Expert Committee on Biological Standardization, TRS 962, Annex 3[EB/OL].(2006-11-30) [2022-09-21].https://www.who.int/publications/i/item/9789241209625
[20] WOLFF J A, MALONE RW, WILLIAMS P, et al. Direct gene transfer into mouse muscle in vivo[J].Science, 1990, 247(4949):1465
